HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Arthur I Sagalowsky Selected Research

Transitional Cell Carcinoma

3/2008Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
2/2008Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival.
3/2007Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
3/2007Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
2/2007Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
1/2007Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy.
12/2006Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
12/2006Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
11/2006Nomograms provide improved accuracy for predicting survival after radical cystectomy.
10/2006Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Arthur I Sagalowsky Research Topics

Disease

58Neoplasms (Cancer)
01/2020 - 02/2002
51Carcinoma (Carcinomatosis)
02/2021 - 02/2002
50Urinary Bladder Neoplasms (Bladder Cancer)
01/2016 - 03/2004
18Transitional Cell Carcinoma
03/2008 - 03/2004
12Neoplasm Metastasis (Metastasis)
10/2014 - 03/2004
12Carcinoma in Situ
01/2014 - 11/2005
9Renal Cell Carcinoma (Grawitz Tumor)
01/2020 - 10/2006
8Disease Progression
10/2010 - 02/2007
6Prostatic Neoplasms (Prostate Cancer)
05/2010 - 03/2004
5Margins of Excision
01/2020 - 06/2004
5Lymphatic Metastasis
10/2010 - 12/2006
3Kidney Neoplasms (Kidney Cancer)
01/2020 - 03/2013
2Necrosis
01/2016 - 10/2014
2Thrombosis (Thrombus)
09/2015 - 06/2011
2Extranodal Extension
07/2007 - 06/2004
1Non-Muscle Invasive Bladder Neoplasms
11/2016
1Cysts
04/2015
1Hematuria
04/2015
1Nephrolithiasis
04/2015
1Carcinogenesis
06/2014
1Embryonal Carcinoma
05/2014
1Hypoxia (Hypoxemia)
03/2013
1Wilms Tumor (Wilm's Tumor)
10/2012
1Testicular Germ Cell Tumor
09/2012
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
09/2012
1Solitary Kidney
10/2009
1Obesity
08/2009
1Residual Neoplasm
08/2009
1Urologic Neoplasms (Urological Cancer)
11/2008

Drug/Important Bio-Agent (IBA)

16Biomarkers (Surrogate Marker)IBA
11/2016 - 02/2007
7nuclear matrix protein 22IBA
07/2009 - 03/2004
6CyclinsIBA
11/2016 - 12/2006
6SurvivinIBA
11/2009 - 02/2007
5Proteins (Proteins, Gene)FDA Link
08/2014 - 02/2002
5Prostate-Specific Antigen (Semenogelase)IBA
07/2007 - 02/2002
3Alkaline PhosphataseIBA
01/2016 - 10/2014
3Biological ProductsIBA
01/2016 - 04/2007
3Tumor Biomarkers (Tumor Markers)IBA
11/2011 - 09/2006
2Cisplatin (Platino)FDA LinkGeneric
08/2015 - 06/2008
2TOR Serine-Threonine KinasesIBA
11/2014 - 03/2013
2CreatinineIBA
09/2012 - 09/2003
2AndrogensIBA
05/2010 - 02/2010
2Cyclin D1IBA
11/2007 - 12/2006
2DNA (Deoxyribonucleic Acid)IBA
04/2007 - 02/2002
1Immune Checkpoint InhibitorsIBA
01/2020
1MethyltransferasesIBA
07/2018
1Enhancer of Zeste Homolog 2 ProteinIBA
07/2018
1AntibodiesIBA
12/2017
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
12/2015
1LipidsIBA
12/2015
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
09/2015
1Pyruvate KinaseIBA
04/2015
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2015
1Angiopoietin-2IBA
04/2015
1Insulin-Like PeptidesIBA
08/2014
1Carrier Proteins (Binding Protein)IBA
08/2014
1Messenger RNA (mRNA)IBA
08/2014
1CateninsIBA
06/2014
1Cyclin EIBA
04/2014
1Cyclin-Dependent Kinases (cdk Proteins)IBA
09/2013
1Cyclin-Dependent Kinase Inhibitor p27IBA
09/2013
1Monoclonal AntibodiesIBA
09/2013
1AntigensIBA
09/2013
1TensinsIBA
03/2013
1Phosphatidylinositols (Phosphatidylinositol)IBA
03/2013
1Phosphoric Monoester Hydrolases (Phosphatases)IBA
03/2013
1Cell Cycle ProteinsIBA
02/2012
1PlatinumIBA
10/2011
1Sunitinib (Sutent)FDA Link
06/2011
1human ERBB2 proteinIBA
10/2010
1Indicators and Reagents (Reagents)IBA
08/2010
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
05/2010
1Thrombospondin 1IBA
05/2010
1CI 22IBA
01/2010
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2008
1GemcitabineFDA Link
06/2008
1Methotrexate (Mexate)FDA LinkGeneric
06/2008
1Vinblastine (Vinblastine Sulfate)FDA Link
06/2008
1Tumor Viral Antigens (Large T Antigen)IBA
08/2007

Therapy/Procedure

55Cystectomy
01/2016 - 09/2005
19Lymph Node Excision (Lymph Node Dissection)
05/2014 - 05/2006
18Therapeutics
01/2020 - 09/2006
15Nephroureterectomy
02/2021 - 07/2008
14Adjuvant Chemotherapy
05/2013 - 10/2006
12Drug Therapy (Chemotherapy)
08/2015 - 12/2006
8Nephrectomy
01/2020 - 04/2004
7Neoadjuvant Therapy
12/2020 - 10/2006
5Prostatectomy (Retropubic Prostatectomy)
07/2007 - 02/2002
4Radiofrequency Ablation
01/2016 - 07/2002
3Urinary Diversion (Ileal Conduit)
01/2007 - 04/2002
2Adjuvant Radiotherapy
12/2006 - 10/2006
2Radiotherapy
11/2006 - 03/2004
1Length of Stay
01/2020
1Immunotherapy
01/2020
1Transurethral Resection of Bladder
11/2016
1Orchiectomy (Orchidectomy)
05/2014
1Combined Modality Therapy
12/2012
1Investigational Therapies (Experimental Therapy)
06/2011
1Molecular Targeted Therapy
06/2011
1Conservative Treatment
07/2008